恒瑞医药(01276.HK)：子公司“HRS-1780片”获临床试验批准

Group 1 - The core announcement is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of HRS-1780 tablets [1] - HRS-1780 is a tablet formulation intended for clinical trials, with the application numbers CXHL2500992 and CXHL2500993 [2] - The approval indicates that HRS-1780 meets the requirements for drug registration as per the Drug Administration Law of the People's Republic of China, allowing the initiation of clinical trials [2] Group 2 - The intended indication for HRS-1780 is the treatment of adult patients with heart failure and a left ventricular ejection fraction of ≥40% [2]